Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

Trial Profile

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Jun 2018

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Therapeutic Use
  • Acronyms VOCAL
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2018 According to the Vertex Pharmaceuticals media release, data from this trial were presented at the 41st European Cystic Fibrosis Conference 2018.
    • 24 May 2018 New trial record
    • 23 May 2018 Results of interim analysis (n=73) describing healthcare resource utilization (HCRU) over 12 months from the VOCAL study presented at the 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top